Retatrutide is a peptide investigated for weight management and metabolic health. It activates three receptor types: GLP-1, GIP and glucagon. You will often see it called a triple agonist, meaning one compound engages three biological targets.
Weight management and metabolic research
GLP-1 and GIP are hormones involved in metabolic signalling. Glucagon has a different role in energy regulation. Retatrutide brings these pathways together, which makes it a useful comparison with semaglutide and tirzepatide. Counting receptors is a way to understand the mechanism; it is not a stand-alone ranking of benefits.
Reading the evidence
A published phase 2 trial in adults with obesity investigated an assigned retatrutide formulation and measured body-weight change over time. Human trial evidence is more directly informative about that study population than a cell experiment, but the population, study formulation, duration and adverse events all remain part of the result. This catalogue material is not the clinical trial product.
Retatrutide vs semaglutide vs tirzepatide
Semaglutide targets GLP-1. Tirzepatide targets GIP and GLP-1. Retatrutide adds glucagon-receptor activity. Compare the actual trial populations and endpoints alongside these mechanisms. Percentage weight changes from separate trials are not a head-to-head comparison. Our three-way guide explains the differences and separates educational references from products available in the confirmed catalogue.
From research to product information
This profile explains the compound. The Retatrutide product page lists current sizes, prices, specifications and linked batch records. Keep those product facts separate from findings about a different study material.
Original source
Read the original paper on PubMed
Keep learning
How to read peptide research · How to read a COA
Read the trial as well as the result
A trial phase describes a research purpose, not an approval decision. Read the clinical-trial explanation before comparing study populations, endpoints and follow-up. For the submitted material, verify the original analytical report separately.
Explore this topic further
Reading the evidence
Three receptors, one defined study context
Receptor activity describes the research pathway. The phase 2 source identifies a particular trial formulation, study population, comparator and duration. It is not a test of a catalogue vial, and separate trial results do not create a head-to-head comparison.

